• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention aims to provide a food for improving intestinal environment by promoting proliferation of intestinal lactic acid bacteria and the like. The present invention provides a food for improving intestinal environment, containing a combination of (1) a composition containing γ-polyglutamic acid or γ-polyglutamic acid, and (2) a composition containing oligosaccharide or oligosaccharide.
    公开号:EP3692814A1
    申请号:EP18864664.0
    申请日:2018-10-05
    公开日:2020-08-12
    发明作者:Keishi Kameyama；Momoka TSUNEYOSHI
    申请人:Ajinomoto Co Inc；
    IPC主号:A23L33-00
    专利说明:
    [0001] The present invention relates to a food for improving intestinal environment by promoting proliferation of intestinal lactic acid bacteria and bifidobacteria. [Background Art]
    [0002] It is important for prevention of various diseases and promotion and maintenance of health to promote proliferation of beneficial bacteria such as intestinal lactic acid bacteria, bifidobacteria and the like and improve intestinal environment (normalization of intestinal bacterial flora).
    [0003] Patent document 1 describes a bowel movement improvement effect of γ-polyglutamic acid. Non-patent document 1 describes a lactic acid bacteria increase effect of γ-polyglutamic acid. It is known that oligosaccharides are difficult to digest and absorb in the stomach and small intestine, and that they reach the large intestine and become a bait for beneficial bacteria such as lactic acid bacteria, bifidobacteria and the like. However, it is not known that the combined use of γ-polyglutamic acid and oligosaccharide remarkably increases lactic acid bacteria and bifidobacteria compared to when they are each used alone. [Document List][Patent document]
    [0004] patent document 1: JP-A-2007-22982 [non-patent document]
    [0005] non-patent document 1: J. Microbiol. Biotechnol. (2017), 27(2), 412-415 [SUMMARY OF THE INVENTION][Problems to be Solved by the Invention]
    [0006] The present invention aims to provide a food for improving intestinal environment by promoting proliferation of intestinal lactic acid bacteria and bifidobacteria. [Means of Solving the Problems]
    [0007] The present inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that the combined use of γ-polyglutamic acid and oligosaccharide remarkably increases lactic acid bacteria and bifidobacteria compared to when they are each used alone. The present inventors have conducted further studies based on the above-mentioned finding and completed the present invention.
    [0008] That is, the present invention provides the following.[1] A food for improving intestinal environment, comprising a combination of (1) a composition comprising γ-polyglutamic acid or γ-polyglutamic acid, and (2) a composition comprising oligosaccharide or oligosaccharide. [2] The food of the above-mentioned [1], wherein the composition comprising oligosaccharide is in a liquid form. [3] The food of the above-mentioned [2], wherein the composition comprising oligosaccharide in a liquid form is a liquid comprising oligosaccharide. [4] The food of the above-mentioned [2], wherein the composition comprising oligosaccharide in a liquid form is a drink comprising oligosaccharide. [Effect of the Invention]
    [0009] According to the present invention, a food having a remarkably superior promoting effect on the proliferation of lactic acid bacteria and bifidobacteria as compared to when each is used singly and a function to improve intestinal environment can be provided by supplying a combination of γ-polyglutamic acid and oligosaccharide. [Brief Description of the Drawings]
    [0010] Fig. 1 shows the results (mean±standard error, n=6) of Experimental Example 1 (y-polyglutamic acid and fructo-oligosaccharide addition test to human feces suspension). Fig. 2 shows the results (mean±standard error, n=3) of Experimental Example 2 (γ-polyglutamic acid and various oligosaccharide addition test to human feces suspension). Fig. 3 shows the results (mean±standard deviation, n=3) of Experimental Example 3 (γ-polyglutamic acid and fructo-oligosaccharide administration test to swine). Fig. 4 shows the results (mean±standard deviation, n=6, *: P<0.05, Student's t-test) of Experimental Example 4 (γ-polyglutamic acid and fructo-oligosaccharide administration test to swine). [Description of Embodiments]
    [0011] The present invention is described in detail in the following.
    [0012] The food of the present invention for improving intestinal environment is composed of a combination of (1) a composition containing γ-polyglutamic acid or γ-polyglutamic acid and (2) a composition containing oligosaccharide or oligosaccharide.
    [0013] The food of the present invention is a combined use food of (1) and (2) in which (1) and (2) are used in combination.
    [0014] In the food of the present invention, (1) and (2) may be simultaneously formulated and contained in the same preparation (food), or (1) and (2) may be formulated separately and ingested simultaneously or at different times by the same route or different routes. That is, the food of the present invention includes a food containing (1) and (2) in one preparation, and a food combining (1) and (2) formulated separately.
    [0015] In the present specification, food is a concept that broadly encompasses foods that can be taken orally (excluding pharmaceuticals) and includes not only so-called "food" but also drink, health supplement, food with health claims (e.g., food for specified health uses, foods with functional claims), supplement and the like.
    [0016] In the present specification, "improvement of intestinal environment" refers to relatively increasing lactic acid bacteria and/or bifidobacteria present in the lower gastrointestinal tract. To increase relatively means to promote predominance of lactic acid bacteria and/or bifidobacteria in the intestinal bacterial flora. The predominance of lactic acid bacteria and bifidobacteria in the intestinal bacterial flora can be confirmed by measuring the amount of lactic acid bacteria and the amount of bifidobacteria in feces by quantitative PCR or the like.
    [0017] In the present specification, the "lower gastrointestinal tract" means ileum, cecum, colon and rectum. (1) Composition containing γ-polyglutamic acid or γ-polyglutamic acid
    [0018] In the present invention, γ-polyglutamic acid can be used as it is, or a composition containing γ-polyglutamic acid can be used as (1).
    [0019] In the present invention, γ-polyglutamic acid is preferably, for example, γ-polyglutamic acid which is a polymer in which about 30 to about 5000 D-glutamic acids and L-glutamic acids are mixed and bonded in a ratio of about 8:2.
    [0020] The γ-polyglutamic acid is also referred to as polyglutamic acid.
    [0021] As γ-polyglutamic acid, a commercially available product (e.g., CALTAKE (trade name) manufactured by Ajinomoto Co., Inc.) can also be used.
    [0022] The form of the composition containing γ-polyglutamic acid of the present invention is not particularly questioned and may be, for example, powder, granule (including fine granules), tablet, hard capsule, soft capsule, liquid (e.g., solution, suspension, milky lotion), drink, jelly, pudding, yogurt, candy, chewing gum or the like. These can be produced by a known method. For example, γ-polyglutamic acid is mixed with carriers (e.g., excipient, binder, disintegrant, lubricant, solvent) and powder, granule, tablet, capsule, liquid and the like can be produced by a method known in the field of food preparation or pharmaceutical preparation. In addition, they can also be produced by adding and mixing γ-polyglutamic acid to and with food and drink (e.g., water, soft drink). (2) Composition containing oligosaccharide or oligosaccharide
    [0023] In the present invention, oligosaccharide can be used as it is or a composition containing oligosaccharide can be used as (2).
    [0024] Examples of the oligosaccharide in the present invention include coffee bean manno-oligosaccharide, lactosucrose oligosaccharide, galacto-oligosaccharide, fructo-oligosaccharide, soybean oligosaccharide, xylo-oligosaccharide and isomalto-oligosaccharide, and fructo-oligosaccharide, coffee bean manno-oligosaccharide, isomalto-oligosaccharide or galacto-oligosaccharide is preferable. One or more kinds of oligosaccharides can be used in combination.
    [0025] The form of the composition containing oligosaccharide of the present invention is not particularly questioned and may be, for example, powder, granule (including fine granules), tablet, hard capsule, soft capsule, liquid (e.g., solution, suspension, milky lotion, liquid seasoning (e.g., liquid sweetener)), drink, jelly, pudding, yogurt, candy, chewing gum or the like. Among these, a liquid form (e.g., liquid (e.g., solution, suspension, milky lotion, liquid seasoning (e.g., liquid sweetener)), drinks) is preferable.
    [0026] These can be produced by a known method. For example, oligosaccharide is mixed with carriers (e.g., excipient, binder, disintegrant, lubricant, solvent) and powder, granule, tablet, capsule, liquid and the like can be produced by a method known in the field of food preparation or pharmaceutical preparation. In addition, they can also be produced by adding and mixing oligosaccharide to and with food and drink (e.g., water, soft drink). In addition, they can also be produced by adding and mixing a liquid sweetener containing oligosaccharide to and with food and drink (e.g., water, soft drink).
    [0027] As mentioned above, the food of the present invention includes a food containing the above-mentioned (1) and (2) in one preparation, and a food combining the above-mentioned (1) and (2) formulated separately.
    [0028] As the food combining (1) and (2) formulated separately, for example, a food combining (1) in the form of granule, tablet, hard capsule or soft capsule containing γ-polyglutamic acid, and (2) in the form of drink containing oligosaccharide can be mentioned.
    [0029] In the present invention, (1) and (2) may be ingested simultaneously or at different times by the same route or different routes. Specifically, for example, a capsule (e.g., hard capsule, soft capsule) containing γ-polyglutamic acid, granule, tablet and the like may be ingested together with oligosaccharide-containing drink.
    [0030] The form of the food containing (1) and (2) in one preparation is not particularly questioned and may be, for example, powder, granule (including fine granules), tablet, hard capsule, soft capsule, liquid (e.g., solution, suspension, milky lotion, liquid seasoning (e.g., liquid sweetener)), drink, jelly, pudding, yogurt, candy, chewing gum or the like. These can be produced by a known method.
    [0031] The ingestion amount of γ-polyglutamic acid in the food for improving intestinal environment of the present invention is generally 0.1 - 100 g, preferably 0.1 - 50 g, more preferably 1 - 20 g, per day for an adult (body weight 60 kg).
    [0032] The ingestion amount of oligosaccharide in the food for improving intestinal environment of the present invention is generally 0.1 - 100 g, preferably 0.1 - 50 g, more preferably 1 - 20 g, per day for an adult (body weight 60 kg).
    [0033] In the food for improving intestinal environment of the present invention, the weight ratio of oligosaccharide and γ-polyglutamic acid (oligosaccharide:y-polyglutamic acid) is preferably 1:0.05 - 20, more preferably 1:0.1 - 10, further preferably 1:0.1 - 5, further more preferably 1:0.1 - 3, particularly preferably 1:0.2 - 2.
    [0034] The food of the present invention can be safely given to human and animals other than human (e.g., mammals and birds such as domestic animals, poultry, experiment animals and the like). The ingestion form for animals other than human may be addition to a feed.
    [0035] In another embodiment of the present invention, "a commercial package containing a food containing a combination of (1) a composition containing γ-polyglutamic acid or γ-polyglutamic acid and (2) a composition containing oligosaccharide or oligosaccharide, and a written matter describing explanation relating to use for improving intestinal environment", "a food with an indication that it is used for improving intestinal environment, which contains a combination of (1) a composition containing γ-polyglutamic acid or γ-polyglutamic acid and (2) a composition containing oligosaccharide or oligosaccharide", "a food for enhancing an intestinal environment improving effect containing a combination of (1) a composition containing γ-polyglutamic acid or γ-polyglutamic acid and (2) a composition containing oligosaccharide or oligosaccharide" and "a food for enhancing an intestinal environment improving effect of a composition containing oligosaccharide or oligosaccharide, which food is a composition containing γ-polyglutamic acid or γ-polyglutamic acid" can be mentioned. The "composition containing γ-polyglutamic acid or γ-polyglutamic acid", "a composition containing oligosaccharide or oligosaccharide", "intestinal environment improvement", "ingestion amount of γ-polyglutamic acid" and "ingestion amount of oligosaccharides" are the same as exemplifications and definitions indicated for the above-mentioned food for improving intestinal environment. [Example]
    [0036] The present invention is explained in more detail in the following by referring to Experimental Examples, Examples, Comparative Examples and Reference Examples, which are not to be construed as limitative.
    [0037] Abbreviations mean the following. γ-PGA: γ-polyglutamic acid (Poly-γ-Glutamic Acid) FOS: fructo-oligosaccharide PBS: phosphate buffered saline CMOS: coffee bean manno-oligosaccharide IMOS: isomalto-oligosaccharide GOS: galacto-oligosaccharide [Experimental Example 1] Addition test of γ-PGA and fructo-oligosaccharide to human feces suspension
    [0038] The PBS solutions of Examples and Comparative Examples shown in Table 1 were prepared and used as media for feces culture. PBS alone was used as a negative control. As γ-PGA, polyglutamic acid "CALTAKE" manufactured by Ajinomoto Co., Inc. was used, and as FOS, fructo-oligosaccharide manufactured by Wako Pure Chemical Industries, Ltd. was used.
    [0039] Thereafter, 10 ml each was dispensed into glass vials and the glass vials were sterilized by autoclave, made anaerobic, and sealed with a butyl rubber stopper. The feces suspension was prepared by collecting about 10 g of feces from 6 healthy individuals (3 men and 3 women) in their 20s to 40s and suspending same in 80 ml of anaerobic PBS. The feces suspension was added to each vial by 0.5 ml, placed in an incubator at 37°C, and anaerobically cultured for 4 days with tumble blending once per day. After completion of the culture, an intestinal bacterial pellet was obtained from the whole amount of the culture medium by centrifugation (8,000xg, for 5 min). DNA was extracted from this pellet using ISOFECAL for BeadsBeat (manufactured by NIPPON GENE CO., LTD.), and quantitative PCR was performed using GeneAce SYBR qPCR Mix α (manufactured by NIPPON GENE CO., LTD.). Quantitative PCR was performed under the conditions of 45 cycles of 95°C for 30 sec and 60°C for 60 sec after 95°C for 10 min. Primers for quantitative PCR used for detection of lactic acid bacteria group (mainly, Lactobacillus spp.) were as follows.LAB-F: 5'-AGCAGTAGGGAATCTTCCA-3' (SEQ ID NO: 1) (Appl Environ Microbiol. 67(6): 2578-2585, 2001)LAB-R: 5'-CACCGCTACACATGGAG-3' (SEQ ID NO: 2) (Appl Environ Microbiol. 68(1): 114-123, 2002) [Table 1] medium for feces culture Example 1-1 0.1% γ-PGA and 0.5% FOS-containing PBS solution Example 1-2 0.5% γ-PGA and 0.5% FOS-containing PBS solution Example 1-3 1.0% γ-PGA and 0.5% FOS-containing PBS solution Comparative Example 1-1 0.1% γ-PGA-containing PBS solution Comparative Example 1-2 0.5% γ-PGA-containing PBS solution Comparative Example 1-3 1.0% γ-PGA-containing PBS solution Comparative Example 2 0.5% FOS-containing PBS solution (positive control) Reference Example 1 PBS alone (negative control)
    [0040] Using the results obtained by quantitative PCR, the relative amount when PBS alone (negative control) is 1 was calculated, and the results were normalized with z-score.
    [0041] The results are shown in Fig. 1. The data shows mean of z-score ± standard error (n=6). A significant difference was determined by Dunnet's test using positive control as the control (*: P<0.05).
    [0042] As a result, proliferation of lactic acid bacteria group was not observed when γ-PGA was added alone. However, when 0.5% FOS was added together with γ-PGA, more prominent proliferation of lactic acid bacteria group than that with FOS alone was observed concentration dependent.
    [0043] Thus, in the present invention, a synergistic effect exceeding the additive effect was observed in the proliferation of lactic acid bacteria group by combining γ-PGA and oligosaccharide. [Experimental Example 2] Addition test of γ-PGA and various oligosaccharides to human feces suspension
    [0044] The PBS solutions of Examples and Comparative Examples shown in Table 2 were prepared and used as media for feces culture. PBS alone was used as a negative control. As CMOS, coffee bean manno-oligosaccharide manufactured by Ajinomoto AGF, Inc. was used, as IMOS, isomalto-oligosaccharide manufactured by Wako Pure Chemical Industries, Ltd. was used, and as GOS, galacto-oligosaccharide manufactured by Wako Pure Chemical Industries, Ltd. was used.
    [0045] Feces culture and detection of lactic acid bacteria were performed according to methods similar to those in Experimental Example 1. [Table 2] medium for feces culture Example 2-1 0.1% γ-PGA and 0.5% CMOS-containing PBS solution Example 2-2 0.5% γ-PGA and 0.5% CMOS-containing PBS solution Example 2-3 1.0% γ-PGA and 0.5% CMOS-containing PBS solution Comparative Example 3 0.5% CMOS-containing PBS solution (positive control) Reference Example 2 PBS alone (negative control) Example 3-1 0.1% γ-PGA and 0.5% IMOS-containing PBS solution Example 3-2 0.5% γ-PGA and 0.5% IMOS-containing PBS solution Example 3-3 1.0% γ-PGA and 0.5% IMOS-containing PBS solution Comparative Example 4 0.5% IMOS-containing PBS solution (positive control) Reference Example 3 PBS alone (negative control) Example 4-1 0.1% γ-PGA and 0.5% GOS-containing PBS solution Example 4-2 0.5% γ-PGA and 0.5% GOS-containing PBS solution Example 4-3 1.0% γ-PGA and 0.5% GOS-containing PBS solution Comparative Example 5 0.5% GOS-containing PBS solution (positive control) Reference Example 4 PBS alone (negative control)
    [0046] Using the results obtained by quantitative PCR, the relative amount when PBS alone (negative control) is 1 was calculated, and the results were normalized with z-score.
    [0047] The results are shown in Fig. 2. The data shows mean of z-score ± standard error (n=3). A significant difference was determined by Dunnet's test using positive control as the control (*: P<0.05).
    [0048] As a result, all oligosaccharides showed remarkable proliferation of lactic acid bacteria group by combining with γ-PGA, compared to when oligosaccharide was used alone.
    [0049] Thus, in the present invention, a synergistic effect exceeding the additive effect was observed in the proliferation of lactic acid bacteria group by combining γ-PGA and oligosaccharide irrespective of the type thereof. [Experimental Example 3] Administration test of γ-PGA and FOS to pigs
    [0050] Six 2 to 3 months-old male pigs (HI-COOP SPF pig LWD) were purchased from ZEN-NOH, divided into 2 test groups each containing 3 pigs such that the average body weight was uniform and bred for 4 weeks at 3 pigs/pen. In each test group, 400 g/head of pig MIRAI CEX (ZEN-NOH) was fed twice per day. In each test group, the test substance was administered by the dosage and method shown in Table 3. Polyglutamic acid "CALTAKE" manufactured by Ajinomoto Co., Inc. was used as γ-PGA, and fructo-oligosaccharide "Mayoligo P granule" manufactured by Meiji Food Materia Co., Ltd. was used as FOS. After 4 weeks from the start of administration, the cecum was collected, and lactic acid bacteria in the cecal contents was examined by quantitative PCR in the same manner as in Experimental Examples 1 and 2. [Table 3] dose dose and administration method of test substance Example 5 FOS: administration of 10 g of mixed feed for every meal γ-PGA: oral administration of two cellulose capsules after every meal, each encapsulating 3 g Comparative Example 6 FOS: administration of 10 g of mixed feed for every meal placebo: oral administration of two empty cellulose capsules after every meal
    [0051] The results are shown in Fig. 3. The data shows the relative amount when the copy number of DNA derived from lactic acid bacteria of Comparative Example 6 is 1 (mean ± standard deviation, n=3).
    [0052] As a result, an effect of proliferating pig intestinal lactic acid bacteria by about 2 times on average than by the ingestion of FOS alone could be confirmed by the combination of γ-PGA and FOS. [Experimental Example 4] Administration test of γ-PGA and FOS to pigs
    [0053] Twenty-four 2 to 3 months-old male pigs (HI-COOP SPF pig LWD) were purchased from ZEN-NOH, divided into 4 test groups each containing 6 pigs such that the average body weight was uniform and bred for 4 weeks at 3 pigs/pen. In each test group, 400 g/head of pig MIRAI CEX (ZEN-NOH) was fed twice per day. In each test group, the test substance was administered by the dosage and method shown in Table 4. Polyglutamic acid "CALTAKE" manufactured by Ajinomoto Co., Inc. was used as γ-PGA, and fructo-oligosaccharide "Mayoligo P granule" manufactured by Meiji Food Materia Co., Ltd. was used as FOS. After 4 weeks from the start of administration, the cecum was collected, and bifidobacteria in the cecal contents were examined by quantitative PCR. Quantitative PCR was performed under the conditions of 45 cycles of 95°C for 30 sec and 60°C for 60 sec after 95°C for 10 min. Primers for quantitative PCR used for detection bifidobacteria are as follows.g-Bifid-F: 5'-CTCCTGGAAACGGGTGG-3' (SEQ ID NO: 3)g-Bifid-R: 5'-GGTGTTCTTCCCGATATCTACA-3' (SEQ ID NO: 4) [Table 4] dose and administration method of test substance Example 6 FOS: administration of 6 g of mixed feed for every meal γ-PGA: oral administration of one cellulose capsule after every meal, each encapsulating 3 g Example 7 FOS: administration of 6 g of mixed feed for every meal γ-PGA: oral administration of one cellulose capsule after every meal, each encapsulating 6 g Comparative Example 7 placebo: oral administration of two empty cellulose capsules after every meal Comparative Example 8 FOS: administration of 6 g of mixed feed for every meal placebo: oral administration of two empty cellulose capsules after every meal
    [0054] The results are shown in Fig. 4. The data shows the relative amounts when the copy number of DNA derived from bifidobacteria in Comparative Example 7 is 1 (mean ± standard deviation, n=6).
    [0055] As a result, an effect of proliferating pig intestinal bifidobacteria by about 10 times on average than by the ingestion of FOS alone could be confirmed by the combination of γ-PGA and FOS. In particular, a remarkable increasing effect on bifidobacteria than by the ingestion of FOS alone could be confirmed by additional ingestion of γ-PGA in half the ingestion amount of FOS.
    [0056] This application is based on patent application No. 2017-195311 filed in Japan, the contents of which are encompassed in full herein.
    权利要求:
    Claims (4)
    [0001] A food for improving intestinal environment, comprising a combination of (1) a composition comprising γ-polyglutamic acid or γ-polyglutamic acid, and (2) a composition comprising oligosaccharide or oligosaccharide.
    [0002] The food according to claim 1, wherein the composition comprising oligosaccharide is in a liquid form.
    [0003] The food according to claim 2, wherein the composition comprising oligosaccharide in a liquid form is a liquid comprising oligosaccharide.
    [0004] The food according to claim 2, wherein the composition comprising oligosaccharide in a liquid form is a drink comprising oligosaccharide.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP2021063079A|2021-04-22|Glycan therapeutic agents and related methods
    Malaguarnera et al.2014|Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives
    Al Hafid et al.2015|Phenylketonuria: a review of current and future treatments
    JP6494859B2|2019-04-03|Composition comprising a bacterial strain
    US9637729B2|2017-05-02|Cell and enzyme compositions for modulating bile acids, cholesterol and triglycerides
    KR20180105724A|2018-09-28|Composition comprising bacterial strains
    AU2017101478A4|2017-11-30|Probiotic compositions and uses thereof for treatment of obesity-related disorders
    EP3520800A1|2019-08-07|Compositions comprising bacterial strains
    Charbonneau et al.2016|Sialylated milk oligosaccharides promote microbiota-dependent growth in models of infant undernutrition
    Schoster et al.2014|Probiotic use in horses–what is the evidence for their clinical efficacy?
    Fedorak et al.2004|Probiotics and the management of inflammatory bowel disease
    AU2012267516B2|2017-08-10|Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes
    ES2759556T3|2020-05-11|Oligosaccharic mixture from human milk
    Bringiotti et al.2014|Intestinal microbiota: the explosive mixture at the origin of inflammatory bowel disease?
    TWI574633B|2017-03-21|Compositions comprising probiotic and prebiotic components and mineral salts, with lactoferrin
    US20160220620A1|2016-08-04|Probiotic compositions for use in the treatment of bowel diseases
    Vanderhoof et al.1998|Use of probiotics in childhood gastrointestinal disorders
    JP6116568B2|2017-04-19|Method for preventing and / or treating insulin resistance
    Caballero-Franco et al.2007|The VSL# 3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells
    US20150265661A1|2015-09-24|Prebiotic effect of sialyllactose
    CA2825980C|2017-10-24|Bifidobacterium bifidum strains for application in gastrointestinal diseases
    Jones et al.2004|Microencapsulated genetically engineered Lactobacillus plantarum 80 | for bile acid deconjugation and its implication in lowering cholesterol
    AU2001231746C1|2005-10-06|Carbohydrate formulation | for enhancement of immune response
    Basso et al.2019|Microbial-based therapies in the treatment of inflammatory bowel disease–an overview of human studies
    AU2018201590A1|2018-03-29|Compositions for the restoration of a fecal microbiota and methods for making and using them
    同族专利:
    公开号 | 公开日
    CN111132561A|2020-05-08|
    US20200237790A1|2020-07-30|
    WO2019070061A1|2019-04-11|
    JPWO2019070061A1|2020-10-22|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2019-04-13| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
    2020-07-10| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
    2020-07-10| PUAI| Public reference made under article 153(3) epc to a published international application that has entered the european phase|Free format text: ORIGINAL CODE: 0009012 |
    2020-08-12| 17P| Request for examination filed|Effective date: 20200327 |
    2020-08-12| AK| Designated contracting states|Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2020-08-12| AX| Request for extension of the european patent|Extension state: BA ME |
    2021-01-13| DAV| Request for validation of the european patent (deleted)|
    2021-01-13| DAX| Request for extension of the european patent (deleted)|
    2021-07-07| A4| Supplementary search report drawn up and despatched|Effective date: 20210607 |
    2021-07-07| RIC1| Information provided on ipc code assigned before grant|Ipc: A23L 33/18 20160101AFI20210531BHEP Ipc: A23L 33/125 20160101ALI20210531BHEP Ipc: A61K 31/702 20060101ALI20210531BHEP Ipc: A61K 38/16 20060101ALI20210531BHEP Ipc: A61P1/00 20060101ALI20210531BHEP Ipc: A61P1/12 20060101ALI20210531BHEP Ipc: A61P 43/00 20060101ALI20210531BHEP Ipc: A23L2/52 20060101ALI20210531BHEP Ipc: A23L2/66 20060101ALI20210531BHEP Ipc: A23L 33/175 20160101ALI20210531BHEP |
    优先权:
    申请号 | 申请日 | 专利标题
    [返回顶部]